IROBOTICS (066430) experienced a significant surge in its stock price, driven by new U.S. and Korean robot-related policies. Despite being primarily a polyethylene packaging company, it is promoting a robot speed-reducer business. However, serious corporate governance issues and a lack of actual robotics revenue raise concerns about its long-term viability.
Rainbow Robotics, a notable KOSDAQ stock, has seen its share price surge, driven by backing from Samsung Electronics and expectations of a robotics and AI supercycle. While the company reports strong revenue growth, it remains loss-making amid extreme valuations. Investors face significant risks, including high dependence on Samsung and valuation fluctuations.
Ecopro’s stock, trading around ₩117,500, benefits from the growing EV and secondary battery markets, with a market cap of approximately ₩13 trillion. Despite significant growth potential, its valuation is volatile, heavily influenced by market trends and investor sentiment, making it a high-risk investment with unpredictable fluctuations.
The company, a small/mid-cap telecom equipment provider, is currently valued at around ₩470 billion with a share price in the high ₩7,000 range. Focused on 5G/6G and data-center capex, it faces earnings volatility and competition. Future performance may hinge on capital expenditure cycles and market dynamics.
The stock currently trades at KRW 692, reflecting a 50% decline over the year amid ongoing losses. Bitgwang Jeonja, a KOSDAQ-listed telecom equipment manufacturer, has seen a change in ownership and faces governance concerns due to significant accumulated losses. Future scenarios depend heavily on market conditions and governance stability.
The company, focused on school uniforms, sports goods, and workwear, currently faces challenges with a declining core revenue from uniforms despite growth in sports merchandising and workwear. Its recent rights offer poses risks of shareholder dilution, while its low PBR suggests undervaluation amid significant market volatility and strategic expansion efforts.
As of November 21, 2025, Ilshin Bio’s share price is KRW 1,852, up 15.5%, with a market cap of KRW 81.9 billion. Despite experiencing revenue declines, signs of recovery emerged in 2025, marked by increased profits and order backlog. Valuations appear reasonable with potential for growth dependent on demand in bio infrastructure and market themes.
ABL Bio’s share price is KRW 178,800 with a market cap of KRW 9.8 trillion, reflecting a substantial 500% annual return. Despite a significant Q3 revenue decline, future expectations hinge on recent partnerships with GSK and Lilly. The company’s high valuation and volatile stock pattern pose risks, urging cautious investment strategies.
